Kidney Week 2019: Call for Abstracts
ASN will accept submissions for research abstracts and clinical case reports electronically from April 3, 2019 through May 30, 2019 (2:00 p.m. EDT). ASN requires ASN User Logins and completed financial and other relationship DISCLOSURES FOR ALL AUTHORS. Please allow adequate time to gather this information. (The call for late-breaking clinical trials will open in July.)
Table of Contents
- New This Year
- General Guidelines
- Submission Information
- Assignment, Notification & Presentation
- Confidential Advanced Access
New this Year
- 2 new abstract categories: Onco-Nephrology; Women's Health and Kidney Diseases
- There will be a separate Call for Informational Posters on June 12 - July 3, 2019. Submissions must include research services in core facilities at academic or nonprofit institutions as well as ongoing clinical trials open to enrollment. The purpose is to stimulate utilization of research core facilities and enrollment in clinical trials. Abstracts describing clinical trial results are NOT eligible for consideration.
- All types of nephrology-related research are eligible for submission and should address scientific questions, detail clinical observations, or contain preliminary scientific data.
- Abstracts are NOT eligible for consideration if the research will have been presented (oral or poster) at another meeting or press conference prior to the ASN meeting.
- Abstracts are NOT eligible for consideration if the research has been published or accepted for publication by May 30, 2019.
- Posting of un-refereed manuscripts to a community preprint server by authors will not be considered prior publication, provided that the following conditions are met:
- During submission, authors must acknowledge preprint server deposition.
- Versions of a manuscript that have been altered as a result of the peer review process may not be deposited;
- The preprint version cannot be indexed (e.g., in MEDLINE or PubMed).
- Upon ASN publication, authors are responsible for updating the archived preprint version with a link to the ASN Abstract Supplement PDF.
- The preprint server should meet NIH standards for interim research product repositories.
- Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
- The lead author (i.e., individual submitting the abstract and presenting the abstract if accepted) must have the authority to submit the abstract and transfer copyright on behalf of the co-authors and company sponsors.v
- All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.
- Accepted abstracts may be assigned for oral presentation, assigned for poster presentation, and/or published in the ASN Abstract Supplement PDF.
- Important! If your research data are available by May 30, 2019, ASN strongly recommends that you submit your abstract during the regular call for abstracts, rather than holding it for the call for late-breaking clinical trials. The regular call for abstracts has more opportunities for oral presentations and posters than the call for late-breaking clinical trials.
Clinical Case Reports
- Case reports must include uniqueness of the case, clinical findings presented, outcomes documented, and "take-away" lessons (teaching points).
- There is a limit of 2 case report submissions per first author (presenting author).
- Accepted case reports may be assigned for poster presentation and/or published in the ASN Abstract Supplement PDF (generally not oral presentation).
- All research abstracts and clinical case reports ("abstracts") must be submitted electronically through the ASN abstract submission site by Thursday, May 30, 2019, 2:00 p.m. EDT for consideration. (The call for informational posters has different dates of June 12 - July 3, 2019.)
- Lead Author: A lead author must be assigned for each abstract submission.
- This individual is the first author listed in the submission and has the primary responsibility for communications with ASN.
- This individual must have an ASN User Login with current contact information for submission.
- Click here if the lead author has an ASN User Login but forgot his/her password.
- Click here if the lead author needs to create an ASN User Login.
- This individual must have a current financial and other relationship disclosure affidavit on file with ASN. (Click here for the ASN Conflict of Interest and Disclosure Policy.)
- This individual is responsible for ensuring that all co-authors and company sponsors approve the submission, publication, and potential presentation.
- This individual will give the oral or poster presentation if the submission is accepted. The lead author should feel comfortable presenting and answering questions in English.
- Co-Authors: Each co-author must have an ASN User Login with current contact information and must have a current financial and other relationship disclosure affidavit on file with ASN. The co-authors will be listed in the order provided during submission.
- Authors and Contributors: With regard to authorship credit, ASN has adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the current update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: "Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3."
Note the full text of the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals. In addition, with regard to contributors, ASN has adopted the following statement of editorial policy from the Information for Authors of the Annals of Internal Medicine: "Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts (Daskalopoulou, Jacobs). These writers should be acknowledged on the byline or in the Acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The editors consider failure to acknowledge these contributors ghostwriting, which is contrary to Annals' editorial policy."
- An abstract submission may contain a maximum of 2,500 characters, and the count includes characters and spaces in the following: Authors Names, Title, Body, Figure, and Table. Figure count is determined by image height but will not exceed 560 characters. Table count is 50 characters per row. Please note that Author Institutions do not count towards the character count.
- The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. An abstract may be submitted and paid for, then returned to draft, edited, and resubmitted for no additional fee before May 30, 2019 at 11:59 p.m. If the lead author does not receive an email confirmation within two business days of submission, please email email@example.com immediately. Lack of email confirmation indicates that ASN did not receive the submission.
- There is no limit to the number of research abstracts that an individual may submit. There is a limit of 2 clinical case reports per first author (presenting author). The $65 processing fee per submission is nonrefundable. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
- Upon abstract submission, the lead author and co-authors agree to all copyright transfer terms and the ASN embargo policy.
- Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers.
- Changes: It is important that the lead author checks the abstract data carefully before submission. Through May 30, 2019 at 11:59 p.m. EDT, submitted abstracts may be returned to draft, edited, and re-submitted. Between this date/time and June 5, 2019, for submitted abstracts needing minimal changes, the contact author can email firstname.lastname@example.org with the abstract number in the subject line and the ASN Abstract Change Form attached. After June 5, 2019, no changes will be allowed, including author updates. If accepted for presentation/publication, your abstract will be printed as it was submitted with any changes as of June 5, 2019. ASN has the authority to make standard copyediting changes (e.g., spelling errors, capitalizations, abbreviations).
- Withdrawals: The lead author can request abstract withdrawal through June 30, 2019 by emailing email@example.com. Please note the abstract number in the email subject line and the lead author's name in the email body. The $65 processing fee is nonrefundable. After June 30, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.
Assignment, Notification & Presentation
All abstract submissions are peer reviewed and authors' names and institutions are blinded to reviewers. ASN will email notifications to the lead authors of all abstract submissions by August 9, 2019. Accepted abstracts will be assigned to one of the following:
- "High-Impact Clinical Studies" Oral Session: This session for late-breaking clinical trials will be held on Friday, November 8, 2:00-4:00 p.m. Each abstract presentation will be followed by audience questions, facilitated by the session moderator(s).
- Oral Abstract Sessions: Oral Abstract Sessions will be held on Thursday, November 7, Friday, November 8, and Saturday, November 9 at 4:30â€“6:30 p.m. Each abstract presentation is allotted eight minutes followed by an additional four minutes of audience questions, facilitated by the session moderator(s). Abstracts accepted for oral presentations will be included in the ASN Abstract Supplement PDF, which will be posted online by October 11, 2019.
- Poster Presentations: Poster presentations will be available for viewing on Thursday, November 7, Friday, November 8, and Saturday, November 9 at 9:30 a.m. â€“ 4:30 p.m. in the exhibit hall. If accepted for poster presentation, the lead author or a co-author must be available at the poster board at 10:00 a.m. â€“ 12:00 p.m. for presentation and discussion. Abstracts accepted for poster presentations will be included in the ASN Abstract Supplement PDF, which will be posted online by October 11, 2019.
- Publication Only: Some abstracts will be included in the ASN Abstract Supplement but not presented during Kidney Week. To request removal from the Abstract Supplement, the lead author must check the box during the submission process that states "Please do not include my abstract in the ASN Abstract Supplement if my abstract is not selected for an oral or poster presentation." The ASN Abstract Supplement PDF will be posted online by October 11, 2019.
It is the responsibility of the lead authors to share the notifications with their co-authors. If you are a lead author and have not received your notification by August 9, 2019, please email firstname.lastname@example.org and note the abstract number in the email subject line and the lead author's name in the email body.
The presenting authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and make their own housing reservations. Please note that early registration closes on September 5, 2019.
Confidential Advanced Access
All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.